key: cord-0698285-a9zle4yy
authors: Soni, Mamta; Gopalakrishnan, Ram; Vaishya, Raju; Prabu, P.
title: D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases
date: 2020-11-17
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2020.11.007
sha: 26f35f139905fd1987137cd2401e312752f25749
doc_id: 698285
cord_uid: a9zle4yy

BACKGROUND AND AIMS: : COVID-19 is a multi-system disease, with coagulation abnormalities. D-dimer levels are increased in this disease. We aimed to determine the association of D-dimer levels and mortality and to establish its optimal cut off values in predicting mortality. Association of D-dimer levels with Diabetes Mellitus has also been established. METHODS: : Information on 483 patients with confirmed COVID-19 was retrospectively collected and analyzed. The optimal D-dimer cutoff point and C-statistic of routine tests both on admission and during hospital stay were evaluated by receiver operator characteristic (ROC) curve. RESULTS: : The D-dimer elevation (≥0.50 μg/mL) was seen in 80.1% of the hospitalized patients. D-dimer level ≥2.01 μg/mL was a significant predictor of subsequent deaths (P < 0.01; HR, 3.165; 95% CI, 2.013–4.977). The high D-dimer values (≥0.50 μg/mL) were observed in 72 of the 75 (96%) cases with a fatal outcome. Median D-dimer values among non-survivors was 6.34 μg/mL and among survivors it was 0.94 μg/mL. A higher proportion of fatal outcomes occurred in patients with underlying disease (89.0%), most prominent of which was Diabetes Mellitus (66%). The median D-dimer value was found to be significantly high in Diabetic patients (1.68 μg/mL). CONCLUSIONS: : Among the measured coagulation parameters, D-dimer during hospital stay had the highest C-index to predict in-hospital mortality in COVID-19 patients. D-dimer value ≥ 2.01 μg/mL can effectively predict in-hospital mortality in patients with COVID-19. A significant association of increased D-dimer level has been found with Diabetes Mellitus and elderly age.

for D-dimer levels on admission.

Coronavirus disease is caused by severe acute respiratory syndrome

Coronavirus-2 (SARS-CoV-2) (1) . Although it is well documented that COVID-19 is primarily manifested as a respiratory tract infection, the emerging data indicates that it should be regarded as a systemic disease involving multiple systems including cardiovascular, respiratory, gastrointestinal, neurological, hematopoietic, and immune system (2) .

the coagulation cascade (3) . Activation of the coagulation cascade in COVID-19

patients is associated with a hypercoagulable state and adverse clinical outcomes including death. Occurrence of dysfunctional coagulation in COVID-19 patients emphasizes the crucial need for a hemostasis-focused laboratory monitoring and therapeutic management (4) . Currently, the best available laboratory diagnostic marker for COVID-19-associated hemostatic abnormalities (CAHA) is considered to be D-dimer (5) . D-dimer is a biomarker of fibrin formation and degradation that can be measured in the whole blood or in the plasma (6) . Healthy individuals have low levels of circulating D-dimer, whereas elevated levels are found in conditions associated with hyper coagulation and increased fibrinolytic activity.

Elevated levels of D-dimer have also been reported in patients with COVID-19.

Elevated D-dimer at the time of admission and markedly increasing D-dimer levels (3-to 4-fold) over time are associated with high mortality, likely reflecting coagulation activation from infection/sepsis, cytokine storm and impending organ failure (7) . Data on the association between D-dimer levels and mortality in COVID-19 patients has been published and measurement of serial D-dimer has been recommended for COVID-19 patients, however, the optimal cutoff for D-dimer is yet to be well-established (8, 9) .

In this retrospective study, our primary objective was to determine an optimum cut-off value of D-dimer on admission and during the hospital stay to predict mortality. We also assessed the contribution of Prothrombin Time (PT) and

Activated Partial Thromboplastin Time (APTT) to predict mortality independent of D-dimer levels. Association of D-dimer with age, gender, and comorbidities have also been assessed.

The approval for this study was obtained from the Ethics Committee of our institution.

The data on the patients with confirmed COVID-19, admitted to our tertiary care hospital, between April 02, 2020, to July 24, 2020, was retrospectively collected through an electronic records system (EMS) and was analyzed. The information included demographic details, laboratory findings, and clinical details including co-morbidities and disease outcomes. Patient's details were kept confidential.

J o u r n a l P r e -p r o o f and APTT values, on admission, were also extracted.

Coagulation parameters were analyzed using a Sysmex CS-2400 coagulation analyzer (Sysmex Corporation, Kobe, Japan). D-dimer testing was performed using a latex-enhanced photometric immunoassay (Siemens, Marburg, Germany) and the result was expressed in µg/ml FEU. The laboratory reference interval was 0 to 0.5 µg/ml FEU. The PT testing was performed using Thromborel S and the APTT testing was performed using Actin FSL, both from

Siemens. The laboratory reference interval for PT and APTT was 10-13 seconds and 20-31 seconds, respectively. 

The data of 483 patients with COVID-19 were analyzed in the study, according to our Table 1 . A total of 75 deaths (15.52%) were recorded amongst these admitted patients.

The optimum cutoff value for D-dimer on admission for predicting mortality, was calculated using the ROC curve was 1.44 µg/ml, with a sensitivity of 60.5%, and a specificity of 74.0% ( Table 2 ). The area under the ROC curve (C-index) was 0.683.

The optimum cutoff value for D-dimer for predicting mortality, calculated using the highest D-dimer value during hospital stay was 2.01 µg/ml, with a sensitivity of 73.3%

and a specificity of 70.0%. The area under the ROC curve was 0.789 (Table 2) . For age-adjusted D-dimer, the cutoff value for predicting mortality was 2.1µg/ml, with a sensitivity of 76.5% and a specificity of 63.5%. The area under the ROC curve (Cindex) was 0.766 ( Table 2 suggesting no impact of false positives).

The area under the ROC curve (C-index) of PT was 0.741, while that of APTT was 0.663 indicating PT to be a predictor of mortality in these patients. J o u r n a l P r e -p r o o f Among the measured coagulation parameters, D-dimer during hospital stay had the highest C-index to predict in-hospital mortality in COVID-19 patients.

The D-dimer elevation (≥ 0.50 µg/ml) was seen in 80.1% (387/483) of the hospitalized patients ( Table 1 ). The Median D-dimer value among non-survivors was 6.34 µg/ml and it was 0.94 µg/ml among the survivors (Table2). Kaplan-Meier survival curves for D-dimer levels ( Figure 1 ) showed that D-dimer level ≥2.01µg/ml was a significant predictor of subsequent deaths (P <0.01; HR, 3.165; 95% CI, 2.013-4.977) ( Figure   1 ).The high D-dimer values (≥ 0.50 µg/ml) were observed in 72 of the 75 (96%) cases with a fatal outcome. (Table 1 ) Fifty six of the 75 cases (74.67%) had D-dimer levels of ≥2.01 µg/ml.

The median D-dimer value in elderly was 1.38 µg/ml and in adults it was 0.98 µg/ml (p = 0.05; Table 4 ). Abnormal D-dimer was observed in 89.2% (174/195) of the (Table 3) .

No significant difference in median D-dimer values between genders was noticed.

The median D-dimer values were 1.16 µg/ml and 1.10 µg/ml in male and female patients, respectively (p = 0.69; Table 4 ). The mortality was 16.3% among the male patients (55/338) and 13.3% in the female patients (20/145) (Table3). 

D-dimer is the fibrin degradation products released upon cleavage of cross-linked fibrin by plasmin (9) . D-dimer is routinely utilized clinically in diagnosing disseminated intravascular coagulation (DIC) and those with low pretest probability for deep vein thrombosis (DVT) and pulmonary embolism (PE) (10) . Ddimer elevation has been reported to be one of the commonest laboratory findings noted in COVID-19 patients requiring hospitalization (11) . Studies have shown that rising D-dimer levels during the course of hospitalization are associated with worst long-term outcomes (12) . In one study D-dimer levels a few days after admission had a stronger correlation with mortality than those at the admission (13) .

In previously published studies, D-dimer value of more than 2 µg/mL on admission has been reported to predict mortality with high sensitivity and specificity. In these studies, the reported all-cause deaths were low and subsequent measurement of ( 14) . The conclusion of the study was based on 17 reported deaths. Our study included data from 75 fatal outcomes, resulting in a closer approximation of the predictive value of the optimal D-dimer levels.

In our study, the median D-dimer level in non-survivors was significantly higher (6.34 µg/ml) than in survivors (0.94 µg/ml). This corroborates with results from previous studies (14) (15) (18) .

International Society of Thrombosis and Hemostasis interim guidance on recognition and management of coagulopathy recommends PT as the next most important test after D-dimer to be performed in patients with COVID-19 (16) . In our study the areas under the ROC curve of PT and APTT were 0.741 and 0.66 respectively, suggesting PT to be a better predictor of disease mortality. Long et.

al. had observed a correlation between increased levels of both PT and APTT and mortality in COVID-19 patients (13) . However, in most published studies APTT values have not differed significantly between patients with mild and severe disease (17) .

In our study, the elevation of D-dimer and mortality was found to be higher in the elderly (>65yrs). 174 of the 195, i.e., 89.2% of elderly patients had abnormal level D-dimer and 39 of 195, i.e., 20.0% were deceased. This finding is comparable to finding by Hui Long et al who reported a mortality of 16.5% in the age group of more than 60 yrs (13) . Out of the total mortality recorded, 52.0% (39/75) were in have also reported similar findings (19) . There was a significant difference in median D-dimer levels between diabetic and nondiabetic patients. The median Ddimer level in diabetic was found to be 1.68 µg/ml. In a recent publication, Mishra et al. have reported an association of diabetes with increased D-dimer levels in moderately sick COVID 19 patients (20) . Similar to our study, in their study also J o u r n a l P r e -p r o o f

A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes

Hematological findings and complications of COVID-19

COVID-19 and Coagulopathy : Frequently Asked Questions

Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19

A proposal for staging COVID-19 coagulopathy

A Test in Context: D-Dimer

COVID-19 and Coagulopathy : Frequently Asked Questions

Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis

Elevated D-Dimer Levels are Associated with Increased Risk of Mortality in COVID-19

High D-dimer levels are associated with poor prognosis in cancer patients

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis

D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis

Evidence of a potential role for D-dimer and Procalcitonin testing used to assess comorbidities of patients hospitalized with COVID-19

Comorbidity and its Impact on Patients with COVID-19

Relation of D-dimer levels of COVID-19 patients with diabetes mellitus

Self-management of diabetes mellitus during the Covid-19 pandemic: Recommendations for a resource limited setting